Based on recommendations from HF guidelines [5], patients with HF and reduced ejection fraction (HFrEF) should receive a renin–angiotensin system (RAS) inhibitor, beta-blocker and mineralocorticoid receptor antagonist (MRA) therapy. This evidence concerns the gene NR3C2 and hydrops fetalis.